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Helicobacter hepaticus, a Recently Recognized Bacterial
Pathogen, Associated with Chronic Hepatitis and
Hepatocellular Neoplasia in Laboratory Mice
Gastric carcinoma, one of the most prevalent
human cancers worldwide, is among the neo-
plasms for which epidemiologic evidence of envi-
ronmental causes is strongest. The exact nature
of these environmental causes was obscure until
mounting evidence recently linked chronic infec-
tion of the gastric antrum mucosa by Helicobacter
pylori (a microaerobic, gram-negative, spiral bac-
terium) with elevated cancer risk (1). It is now
recognized that gastric B-cell lymphoma of mu-
cosa-associated lymphoid tissue is also closely
linked to gastric H. pylori infection, and eradica-
tion of the infection with antibiotics can result in
regression of the lymphoma (2,3). This startling
finding has stimulated intense interest in the ge-
nus Helicobacter and related organisms; as a re-
sult, additional species of Helicobacter are now
frequently isolated and characterized from many
non-human hosts. Until 1994, however, only H.
pylori was known to be associated with tumor
development, in humans or in any other animal
species.
In 1992, at the National Cancer Institute’s
Frederick Cancer Research and Development
Center (FCRDC) in Frederick, Maryland, a high
prevalence of liver disease was observed among
certain strains of mice; these mice were untreated
controls in long-term chemical carcinogenesis ex-
periments. Affected strains, notably A/JCr, had
been bred at FCRDC under pathogen-free condi-
tions and were free of known serologically detect-
able murine viruses and parasites; moreover, they
had no histologically demonstrable hepatic abnor-
malities, except for a very low incidence (1% to 2%)
of hepatocellular tumors in mice 15 months of age
or older. Over a very short period, the prevalence
of a histologically distinctive form of hepatitis
increased to virtually 100% in male mice at 1 year
of age (Table 1). The earliest demonstrable lesions
were small, undistinctive foci of hepatic necrosis
seen in young mice aged 2 to 6 months. In older
mice, aged 6 to 10 months, there was a highly
distinctive pericholangitis, consisting of abundant
mononuclear cell infiltrates around bile ducts
within portal triads. The biliary epithelium within
affected ducts was focally swollen, and the luminal
surfaces of damaged epithelial cells were poorly
defined in hematoxylin and eosin-stained sections
(4,5). In livers with extensive lesions, bile ductular
(oval cell) hyperplasia was also prominent. More-
over, mice with hepatitis usually had hepatocellu-
lar tumors, often multiple, that included both
adenomas and carcinomas (4).
Hepatocellular tumors in mice are one of the
most common endpoints in bioassays for chemical
carcinogens. They were not, at that time, known
to be associated with infectious agents. Accord-
ingly, initial efforts to identify the cause of the
hepatitis/hepatocellular tumor syndrome were di-
rected toward possible sources of chemical expo-
sure. The possibility of accidental exposure to
experimental substances within the research ani-
mal facilities was ruled out when liver disease was
identified in mice that had never left the breeding
areas which are located in separate buildings.
Extensive chemical analyses of food, bedding,
water, and other possible sources of toxic sub-
stances had negative results.
Detailed pathologic examination by light mi-
croscopy of tissue sections from diseased livers
was continued, and many special stains were
used. One such stain, Steiner’s silver impregna-
tion procedure for spirochetes (6), revealed in he-
patic tissue uniform bodies that were consistent
in size and shape with bacteria. Homogenates of
fresh liver tissue from diseased mice proved effec-
tive in transmitting hepatitis to A/J mice pur-
chased from commercial sources outside FCRDC,
when given by intraperitoneal injection (5). In
addition, from these homogenates, a motile, spiral
bacterium could be cultivated on blood agar plates
incubated at 37o C under anaerobic or microaero-
bic conditions.
This organism was subsequently characterized
by ultrastructural morphologic examination, bio-
chemical characteristics, and 16S rRNA gene se-
quence. Determined to be a new species related to
H. pylori, it was given the name H. hepaticus (7).
The bacterium is motile and gram negative, 0.2 to
0.3 mm in diameter, 1.5 to 5.0 mm long, and curved
to spiral in shape, with one to several spirals; it
has bipolar sheathed flagella (one at each end) but
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terial cells in other mouse Helicobacter species. H.
hepaticus has strong urease activity, is oxidase
and catalase positive, produces H2S, reduces ni-
trate to nitrite, and grows microaerobically at 37
o
C but not at 25
o C or 42
o C. It is resistant to
cephalothin and nalidixic acid but sensitive to
metronidazole. Photographs illustrating its mor-
phologic structure by light (4,5) and electron
(4,5,7) microscopy have been published. The spe-
cies-defining characteristic of the organism, the
nucleotide sequence of its 16S rRNA gene, has
been used to develop a diagnostic assay based on
polymerase chain reaction (8).
Systematic examination of rodents of all spe-
cies and strains produced at FCRDC, especially
retired breeders, showed that the characteristic
hepatitis and associated bacteria were present in
mice of several strains (A/JCr, DBA/2NCr,
C3H/HeNCr) and that within these strains, the
male mice were more severely affected than the
female. Mice with severe combined immunodefi-
ciencies were especially vulnerable. The precise
location of organisms demonstrable by Steiner
stain within infected liver parenchyma was shown
by transmission electron microscopy to be invari-
ably extracellular and characteristically within
bile canaliculi (4,5). No liver disease was seen in
some strains (e.g., C57BL/6NCr) or in F1 hybrids
between sensitive and resistant strains (e.g.,
B6C3F1). Rodent species other than mice (e.g.,
rats, Syrian hamsters, and guinea pigs) were not
affected.
In infected mice with severe combined immu-
nodeficiency, cecal inflammation was histologi-
cally demonstrable (5), and organisms were
isolated from the mucosa of the large intestine (7),
which may mean that the usual ecologic niche
occupied by H. hepaticus is that of a commensal
colonizer of the intestinal tract (8). Since mice are
coprophagic, it appears highly likely that natural
transmission of the organisms is the oral-fecal
route. Why and how H. hepaticus invades the liver
in mice of certain strains remain to be determined.
Hepatitis is also characteristic of certain other
enteric pathogenic bacteria, such as Campylobac-
ter jejuni (9) that, unlike H. hepaticus, have not
been associated with liver tumor development.
The tissue damage that accompanies persistent
infection by H. hepaticus, H. pylori, and certain
other Helicobacter species may be due, at least in
part, to a soluble, trypsin-sensitive cytotoxin of
high molecular weight produced by these organ-
isms (10). There is no precedent for any direct role
of such a toxin in carcinogenesis. On the other
hand, chronic infections by viruses, bacteria, or
certain parasites are recognized risk factors for
human cancers at various sites. The hypothesis
that chemically reactive, potentially genotoxic,
substances of low molecular weight (including ni-
tric oxide and active oxygen species) generated by
inflammatory cells at the site of chronic infection
may initiate or enhance carcinogenesis has been
examined (11). The hypothesis is under active
investigation in the context of H. hepaticus-asso-
ciated liver disease.
H. hepaticus is susceptible to a number of anti-
biotics; treatment of susceptible, naturally in-
fected 8- to 10-week-old strain A/JCr mice with
single or combined antimicrobial agents has been
evaluated for efficacy in eradicating established
infections (12). Amoxicillin, metronidazole, and
tetracycline administered singly failed to eradi-
cate bacteria from the gastrointestinal tract, but
either amoxicillin or tetracycline, in combination
with metronidazole and bismuth, was effective in
eradicating H. hepaticus from the liver, cecum,
and colon when given by oral gavage for a period
Table 1. Increasing prevalence of hepatitis and hepatocellular neoplasia in control male A/JCr mice at the National Cancer Insti-
tute’s Frederick Cancer Research and Development Center, 1989-1992
a    
Number Age, Mice with Mice with
Date killed of mice in weeks hepatitis (%) liver tumors (%)                       
Jan-Mar 1989 48 47±3  0  0
May-Jul 1989 47 70±60   0   1 (2)
Jan-Apr 1992   6 36±4   2 (33)   0
Jul 1992 16 54 16 (100)   1 (6)
Aug-Oct 1992   6 64±3  5  (83)  3  (50)
Dec 1992 12 77 12 (100) 11 (92)
                                                                                                                                                                                     
aAdapted from ref. 4.
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the carcinogenic process, or in older animals, re-
mains to be established.
The importance of H. hepaticus to humans is
not yet completely known. The organism clearly
has the potential to confound bioassays for chemi-
cal carcinogens, but this potential has no direct
effect on humans. Even though most Helicobacter
species identified to date are characteristically
associated with (and named after) specific mam-
malian host species in which they generally in-
habit the gastrointestinal tract (with or without
causing gastritis or other chronic inflammatory
disease), the potential host range for some species
is quite broad. H. pylori, originally isolated from
humans, has recently been isolated also from the
domestic cat; this raises the possibility that Heli-
cobacter pylori may be a zoonotic pathogen that
can be transmitted from companion animals to
humans (13). Exploring the possibility of zoonotic
transmission of H. pylori, H. hepaticus, or any
other  Helicobacter  species would require isolation
of the organism in question by culture methods.
Serologic methods have not yet been refined to the
level of species specificity. Humans infected with
H. pylori mount a serum antibody response to the
bacteria that is readily detected by enzyme-linked
immunosorbent assays and is considered evidence
of ongoing disease (1); mice infected with H. hepa-
ticus similarly produce serum antibodies to that
species that have been demonstrated by Western
blotting (5). Antisera to H. pylori can be used to
visualize H. hepaticus in mouse liver tissue sec-
tions stained by the avidin-biotin complex immu-
nohistochemical procedure (5). The cross-
reactivity between these two species precludes use
of available serologic methods to establish
whether  H. hepaticus has infected humans.
Regardless of whether H. hepaticus is itself
capable of infecting humans, it serves to demon-
strate that liver tissue can be persistently infected
by at least one member of the genus Helicobacter,
and that liver cancer can be a long-term conse-
quence of such infection. This discovery raises
questions about the existence of a comparable
relationship between liver cancer in humans and
unrecognized bacterial infections. Reviews are un-
der way of tissue blocks from pathology archives
in search of organisms demonstrable by the
Steiner stain in liver sections from human popu-
lations at high risk for liver cancer.
Jerry M. Rice
Laboratory of Comparative Carcinogenesis, National
Cancer Institute, Frederick, Maryland, USA
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